A study conducted by the University of Alabama at Birmingham and recently published in medical journal Lung Cancer suggests adding zoledronic acid to treatment regimens may help mesothelioma cancer victims combat the rare and deadly lung cancer. The drug is in a class of bisphosphonates commonly used to treat osteoporosis and prevent skeletal fractures in cancer patients. Researchers believe the drug may be particularly useful for treating patients in the later stages of malignant mesothelioma.
According to the study, the drug reduced the buildup of fluid in the lungs, known as pleural effusions, and helped growth of new tumor blood vessels in animal trials. Zoledronic acid may help block cell signaling pathways essential for the growth of cancer cells. Although the drug may not be the knockout punch to kill mesothelioma tumors, the research suggests zoledronic acid, sold as Reclast or Zometa for bone disease, can help put the brakes on tumor growth.
Researchers evaluated a number of factors including the patients’ levels of vascular endothelial growth factor (VEGF) and biomarkers mesothelin and osteopontin. Clinicians used positron emission tomography (PET) imaging to track the patient’s’ response to the drug. Patients who failed to respond to treatment were found to have already higher levels of VEGF and osteopontin prior to treatment.